These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9256936)

  • 1. Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient.
    Balotta C; Bagnarelli P; Violin M; Ridolfo AL; Zhou D; Berlusconi A; Corvasce S; Corbellino M; Clementi M; Clerici M; Moroni M; Galli M
    AIDS; 1997 Aug; 11(10):F67-71. PubMed ID: 9256936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.
    Samson M; Libert F; Doranz BJ; Rucker J; Liesnard C; Farber CM; Saragosti S; Lapoumeroulie C; Cognaux J; Forceille C; Muyldermans G; Verhofstede C; Burtonboy G; Georges M; Imai T; Rana S; Yi Y; Smyth RJ; Collman RG; Doms RW; Vassart G; Parmentier M
    Nature; 1996 Aug; 382(6593):722-5. PubMed ID: 8751444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression.
    Michael NL; Chang G; Louie LG; Mascola JR; Dondero D; Birx DL; Sheppard HW
    Nat Med; 1997 Mar; 3(3):338-40. PubMed ID: 9055864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele.
    Furci L; Scarlatti G; Burastero S; Tambussi G; Colognesi C; Quillent C; Longhi R; Loverro P; Borgonovo B; Gaffi D; Carrow E; Malnati M; Lusso P; Siccardi AG; Lazzarin A; Beretta A
    J Exp Med; 1997 Aug; 186(3):455-60. PubMed ID: 9236198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS.
    Abebe A; Demissie D; Goudsmit J; Brouwer M; Kuiken CL; Pollakis G; Schuitemaker H; Fontanet AL; Rinke de Wit TF
    AIDS; 1999 Jul; 13(11):1305-11. PubMed ID: 10449282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MT-2 tropism and CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals.
    Bratt G; Leandersson AC; Albert J; Sandström E; Wahren B
    AIDS; 1998 May; 12(7):729-36. PubMed ID: 9619804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression.
    Xiao L; Rudolph DL; Owen SM; Spira TJ; Lal RB
    AIDS; 1998 Sep; 12(13):F137-43. PubMed ID: 9764773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1.
    Kozak SL; Platt EJ; Madani N; Ferro FE; Peden K; Kabat D
    J Virol; 1997 Feb; 71(2):873-82. PubMed ID: 8995603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion.
    Picard L; Simmons G; Power CA; Meyer A; Weiss RA; Clapham PR
    J Virol; 1997 Jul; 71(7):5003-11. PubMed ID: 9188565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates resulting from the delta ccr5 mutation.
    Rana S; Besson G; Cook DG; Rucker J; Smyth RJ; Yi Y; Turner JD; Guo HH; Du JG; Peiper SC; Lavi E; Samson M; Libert F; Liesnard C; Vassart G; Doms RW; Parmentier M; Collman RG
    J Virol; 1997 Apr; 71(4):3219-27. PubMed ID: 9060685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage.
    Xiao L; Owen SM; Goldman I; Lal AA; deJong JJ; Goudsmit J; Lal RB
    Virology; 1998 Jan; 240(1):83-92. PubMed ID: 9448692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry.
    Simmons G; Wilkinson D; Reeves JD; Dittmar MT; Beddows S; Weber J; Carnegie G; Desselberger U; Gray PW; Weiss RA; Clapham PR
    J Virol; 1996 Dec; 70(12):8355-60. PubMed ID: 8970955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk.
    Zimmerman PA; Buckler-White A; Alkhatib G; Spalding T; Kubofcik J; Combadiere C; Weissman D; Cohen O; Rubbert A; Lam G; Vaccarezza M; Kennedy PE; Kumaraswami V; Giorgi JV; Detels R; Hunter J; Chopek M; Berger EA; Fauci AS; Nutman TB; Murphy PM
    Mol Med; 1997 Jan; 3(1):23-36. PubMed ID: 9132277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor.
    Hill CM; Deng H; Unutmaz D; Kewalramani VN; Bastiani L; Gorny MK; Zolla-Pazner S; Littman DR
    J Virol; 1997 Sep; 71(9):6296-304. PubMed ID: 9261346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group.
    Stewart GJ; Ashton LJ; Biti RA; Ffrench RA; Bennetts BH; Newcombe NR; Benson EM; Carr A; Cooper DA; Kaldor JM
    AIDS; 1997 Dec; 11(15):1833-8. PubMed ID: 9412701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coreceptor utilization of HIV type 1 subtype E viral isolates from Thai men with HIV type 1-infected and uninfected wives.
    Utaipat U; Duerr A; Rudolph DL; Yang C; Butera ST; Lupo D; Pisell T; Tangmunkongvorakul A; Kamtorn N; Nantachit N; Nagachinta T; Suriyanon V; Robison V; Nelson KE; Sittisombut N; Lal RB
    AIDS Res Hum Retroviruses; 2002 Jan; 18(1):1-11. PubMed ID: 11804551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.
    Björndal A; Deng H; Jansson M; Fiore JR; Colognesi C; Karlsson A; Albert J; Scarlatti G; Littman DR; Fenyö EM
    J Virol; 1997 Oct; 71(10):7478-87. PubMed ID: 9311827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele.
    Gorry PR; Zhang C; Wu S; Kunstman K; Trachtenberg E; Phair J; Wolinsky S; Gabuzda D
    Lancet; 2002 May; 359(9320):1832-4. PubMed ID: 12044382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokine receptor CCR5 genotype influences the kinetics of human immunodeficiency virus type 1 infection in human PBL-SCID mice.
    Picchio GR; Gulizia RJ; Mosier DE
    J Virol; 1997 Sep; 71(9):7124-7. PubMed ID: 9261448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals.
    Eugen-Olsen J; Iversen AK; Garred P; Koppelhus U; Pedersen C; Benfield TL; Sorensen AM; Katzenstein T; Dickmeiss E; Gerstoft J; Skinhøj P; Svejgaard A; Nielsen JO; Hofmann B
    AIDS; 1997 Mar; 11(3):305-10. PubMed ID: 9147421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.